Schering-Plough Corporation (NYSE: SGP), a leader in hepatitis research, today reported top- line results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination ...
From: www.centredaily.com
Monday, January 14, 2008
Schering-Plough Reports Top-Line Results of the IDEAL Study
Subscribe to:
Post Comments (Atom)
![Digitalpoint Geo Tracking [Enabled]](http://geo.digitalpoint.com/a.png)
![PingOmatic AutoDiscovery [Enabled]](http://www.genuineblogger.com/images/chicklet-pingomatic.gif)
![Made with Palestinian Efforts [True]](http://www.genuineblogger.com/images/yapalestinets.gif)
No comments:
Post a Comment